

## Ya están aquí las ofertas de Año Nuevo.

# **American Airlines**



Home Earth Heavens Body Brain Culture Tech

Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases

posted on: january 29, 2013 - 3:30pm



In three to six months of life, this genetic alteration in mice -similar to that occurred in human-causes a rapid degeneration in the lower limbs to death for cardiac arrest.

For the first time in the world, researchers at the Center for Biomedical Research of the University of Granada have created mice with a genetic mutation inducing a deficiency in the coenzyme Q10, a rare mitochondrial disease prevailingly affecting children. These mutant mice –which lack the Coq9 gene– will be "a valuable tool for the study and treatment of metabolic encephalopathies and neuromuscular diseases", the researchers state.



Coenzy me Q10 (CoQ10) is a molecule produced in body cells, which functions are crucial to cell metabolism. Their best-known function is their generating energy used by cells and their antioxidant activity. In human, defects in the biosynthetic route cause CoQ10 deficiency, resulting in a syndrome with very heterogeneous symptoms.



 ${\it This is a picture showing hind lower limb paralysis in CoQ10 coenzyme-deficient mice}$ 

(Photo Credit: CIBM - UGR)

To better understand the pathological mechanisms of this disease and learn about the biosynthetic pathway of CoQ, the University of Granada researchers conducted a three-year study to generate mice with a mutation in a gene (Coq9) similar to that found in humans. This gene codifies a protein involved in CoQ biosynthesis.

### Lower Limb Paralysis


Accordikng to professor Luis Carlos López García –the principal investigator of this study – states, "mice with a Coq9 mutation develop a severe encephalomy opathy inducing neural death, astrogliosis and vacuolation of the brain. At three to six months, these mice undergo a rapid degeneration causing lower limp paralysis and death for cardiac arrest. In molecular terms, CoQ deficiency in mice impairs the mitochondrial mechanisms of bioenergy production in the brain, causing a severe bioenergetic deficiency and a slight increase in oxidative damage".

The CoQ9-deficient mutant mouse model generated at the University of Granada "is the first model of CoQ9-deficient mutant mice with mitochondrial encephalomyopathy created worldwide. Currently, there is not any therapy for neuromuscular diseases associated with CoQ10 deficiency, and this mutant model might be useful in the development of an effective therapy for such diseases. In addition, as CoQ10 is also used as a nutritional supplement and in the cosmetics industry, "the CoQ9-deficient mutant mouse model is very useful in the assessment of the effectiveness of nutritional supplements and cosmetics".

The results of this research study —which received financial support from CEI BioTic Granad, the Spanish Ministry of Economy and Competitiveness, the Andalusian Regional Government and the Marie Curie program—have been recently published in the prestigious journal *Human Molecular Genetics*. Researchers from the National Cardiovascular Research Center (CNIC) also participated in the study.

Source: University of Granada

#### Post new comment





#### Popular Today:

- Global investment in renewable energy powers to record \$257 billion
- Study finds significant microorganism populations in middle and upper troposphere
- In-brain monitoring shows memory network
- Hydrogen sulfide: The next anti-aging agent?
- Castles in the desert satellites reveal lost cities of Libya



#### Similar Articles On This Topic:

- Scientists create mouse model of melanoma that generates hope for the use of targeted therapies
- Generation of a severe memory-deficit mutant mouse by exclusively eliminating the kinase activity of CaMKIIalpha
- FSU researcher's 'mutant' proteins could lead to new treatment for heart disease
- Penn-developed mouse model of debilitating lung disease suggests potential treatment regimen
- Caltech researchers show efficacy of gene therapy in mouse models of Huntington's disease